Cannabix Technologies Develops Version 4.0 of THC Breath Analyzer Device
February 1, 2022
Vancouver, British Columbia, February 1, 2022 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace is pleased to report that it has assembled its version 4.0 THC Breath Analyzer (“THCBA”) prototype and portable system for field use. This updated device incorporates planned design changes and feedback from beta-test users. Several components such as the device’s internal sampling chambers, microfluidic sensors and related actuation mechanism have been changed to minimize manufacturing variability and to reduce cost. Initial user testing has commenced and additional devices are being assembled in preparation of delivery to existing and new beta-test sites. Broader field testing and clinical testing to establish V4.0 benchmark standards are planned with this new device. A new image of the THCBA version 4.0 is included in this press release.
The THCBA is a drug screening device for various markets who are seeking a way to quickly (in less than 5 minutes), easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment. The THCBA consists of a handheld device and protective case which houses a sterilization module, sample preparation stage, device recovery station and integrated battery charging system.
The THCBA system is geared to be a cost effective, drug screening tool for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of THC. Employers everywhere are struggling with the limitations of current drug testing technology in identifying recent use of marijuana that may be causing impairment during work hours and differentiating this from recreational and medical use during nonwork hours/days. The Cannabix device allows for more relevant THC detection from breath allowing employers to create an onsite regiment whereby they can perform pre-access testing for recent use of marijuana before and during work hours, instead of testing for drug use when employees are not at work.
Breath testing for THC is a fairer and more relevant test
Current forms of testing for marijuana use can identify THC ranging from minutes to days after actual use, making it impossible to show the difference between the two. Studies¹ have shown that breath is a better indicator of impairment than saliva, blood, or urine because THC is present in breath for a relatively short period of time (1-3 hours) after consumption; whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.